Ref. No.: WOCK/SEC/SE/2025-26/013 5th June, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 **Scrip Code: 532300**	**National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 **NSE Symbol: WOCKPHARMA**

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2025-26/012 dated 2nd June, 2025, please find enclosed herewith a copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 5th June, 2025.

The said Investor Presentation will also be uploaded on the Company's website and can be accessed through the following link:

https://www.wockhardt.com/investors/analyst-investors/presentation/

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Dinesh Mamtura
Digitally signed by Rashmi Dinesh Mamtura
Date: 2025.06.05 09:03:51 +05'30'

Rashmi Mamtura
Company Secretary

Encls: as above

Saving Lives 55 years

WOCKHARDT | LIFE WINS

Investor Presentation

June 2025

Disclaimer

This presentation contains “forward-looking statements” – that is, statements that relate to future, not past events or historical facts. All forward-looking statements are based on judgments derived from the information available to the company at this time. Forward-looking statements can be identified by terminology such as such as “potential,” “expected,” “will,” “planned,” or similar terms. Forward looking statements are based on the current beliefs and expectations of Wockhardt regarding future events, and are subject to various risks and uncertainties, many of which are difficult to predict. Actual results may differ materially from anticipated results. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. We do not undertake any obligation to update any forward-looking statement in this presentation, whether as a result of changes in underlying factors, new information, future events or otherwise. The information in this document have been collected with the purpose to provide interested parties with information about Wockhardt. The information is not comprehensive or complete and thus does not represent an adequate basis for a final decision about an investment. Information contained in this document is to be used for the sole purpose of evaluating potential strategic transactions or partnerships and cannot be used for any other purpose without specific written and prior approval of Wockhardt. The presentation may not be copied, duplicated or transferred to third parties without the prior written approval of Wockhardt.

Information contained in this document is to be used for the sole purpose of evaluating potential strategic transactions or partnerships and cannot be used for any other purpose without specific written and prior approval

Global *Research - driven* multinational

INR 3,033 Cr.
FY25 Income

INR 418 Cr.
FY25 EBITDA

Novel Antibiotics

Biotechnology

Pharmaceuticals

Global *Footprint*

12 manufacturing facilities across globe

2 R&D centers one each in India, UK

	FY25 sales contribution (%)
UK	39%
India	23%
Emerging Markets	23%
Ireland (& other EU)	12%

Stronger business performance

67%
Y-o-Y EBITDA growth[1]

0.01
Net Debt : Equity ratio[2]

20% growth
for biosimilars in emerging markets[3]

INR 326 Cr.
Reduction in debt[4]

1. Growth in FY25 over FY24
2. As on 31st March 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr ; Equity: INR 4,657 Cr.)
3. Growth in FY25 over FY24
4. As at 31st March 2025 vs 31st March 2024 (excluding promoter debt)

Key positives for FY24-25: Development milestones

ZAYNICH® **(WCK 5222)**	▪ Successful completion of global Phase III cUTI study with 20% superiority ▪ Phase II Carbapenem-Resistant Organism study with >90% clinical efficacy ▪ NDA filed with DCGI, India ▪ Compassionate use: 51 lives saved
MIQNAF® **(Nafithromycin)**	▪ Approved & Launched in India ▪ Grant of Breakthrough Medicinal Product (BMP) by Saudi Arabia
ODRATE® **(WCK 6777)**	▪ Completion of Phase I clinical study in collaboration with NIH, USA
FOVISCU® **(WCK 4282)**	▪ Completion of Phase II clinical study
EMROK® / EMROK O®	▪ Emrok treated >100k patients cumulatively; ▪ Launched in other divisions for additional indications
Insulin Aspart	▪ Filed for marketing approval to DCGI, India

Key positives for FY24-25

Sales Growth

Emerging Markets	10%
India Branded Business	4%
UK	8%
Biotech New Business	~$30 Mn

Operational Excellence
Cost reductions & Achievements

- Manufacturing Re-structuring - External to Internal
- Energy cost reduction initiative activated
- Wastage reduced from last year

Capital raise of INR 1,000 Cr. through QIP

Financial Highlight: 67% EBITDA growth[1]

Total Income[1] in INR Cr.



EBITDA[1] in INR Cr.



	FY24	FY25
EBITDA Margin	*9%*	*14%*

1. FY25 vs FY24, excluding exchange rate fluctuations

Net Debt : Equity @ 0.01[1]

Debt Reduction by INR 397 Cr.[1]

Equity INR Cr.



Net Debt[1] INR Cr.



Cash & Cash Equivalents and other Bank Balances INR Cr.



Net Debt-Equity Ratio[1]



1. As at 31st March 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr.; Equity: INR 4,657 Cr.)

Short-term and Mid-term growth drivers

3 years growth drivers		5 years growth drivers
Diabetes Biosimilars for India + Emerging markets	Glargine, Insulin Analogues, Human Insulin	New Insulin Analogues, GLP-1 Analogues
Novel drug discovery	Zaynich® (WCK 5222), Miqnaf® (Nafithromycin), Emrok® & Emrok O®	Foviscu® (WCK 4282), Odrate® (WCK 6777)

New Chemical Entity (Novel Antibiotics)



Wockhardt drug discovery efforts focused on the antibiotics segment

~145

Drug Discovery team with more than 50 PhD's.

~25 years

Focused commitment to Novel Antibiotics research leading to end-to-end Discovery & Development capabilities

6

Programs granted QIDP* status by US FDA denoting unmet needs; abridged trials, faster review and approvals by US FDA

*** Qualified Infectious Disease Product (QIDP)** status granted by US FDA eligible for fast track development process and priority review. QIDP status also grants five year extension to the market exclusivity in the United States

Novel Antibiotics pipeline encompassing all the Resistant Organisms

	Gram Negative Portfolio			Gram Positive Portfolio	
	ZAYNICH® ***(WCK 5222)***	**FOVISCU®** ***(WCK 4282)***	**ODRATE®** ***(WCK 6777)***	**EMROK® / EMROK O®**	**MIQNAF®** **(Nafithromycin)**
					
Status	Global ***Phase III*** Completed	Carbapenem resistant pathogen study (India) completed	***Phase III ongoing***	***Phase I Completed*** ***In collaboration with NIH (US)***	**Launched in India**; Filed in Emerging Markets	**Launched in India**
Potential Indication	cUTI, HABP / VABP (Global) + Carbapenem Resistant infections (India)		cUTI HABP / VABP	cUTI	ABSSSI	CABP / RTI
Target Market	Global		Global	Global	Emerging Market	Emerging Market
Positioning	Destination therapy for difficult-to-treat Gram-ve Klebsiella, Acinetobacter and Pseudomonas		Empiric-use; Carbapenem-sparing Gram-ve	Out-patient therapy for MDR Gram -ve	MDR Gram+ve Anti-MRSA	Macrolide-resistant Respiratory Pathogens, Quinolone-Sparing

ZAYNICH® (WCK 5222)

Establishing β-lactam enhancer - a new class of antibiotic to treat MDR/XDR Gram-negative infections

ZAYNICH® (WCK 5222): New class of antibiotic after >30 years to treat Gram-negative infections

Global Phase III clinical study completed

Global Phase III clinical study: achieved 20% higher (statistically superior) composite cure over gold standard Meropenem

Phase II Carbapenem-Resistance Organism study completed with >90% clinical efficacy

Saved 51 lives so far in compassionate usage including 3 in USA

Patients had failed all available therapies: Penems, Ceftazidime+Avibactam, Cefiderocol, Colistin/Polymyxins; Safety established through extensive usage

Only product granted with investigational breakpoint of 64 mg/L for all major gram-negative pathogens by CLSI, USA

CLSI: Clinical and Laboratory Standards Institute

ZAYNICH® (WCK 5222) Regulatory status

India: Filed to DCGI*
Approval / launch expected in H2 FY25-26.

US: Pre-NDA meeting completed with US FDA in May 2025
Filing to the US FDA in Q2 FY 25-26 with potential launch in FY26-27

Europe & Emerging markets: Filing in H2 FY26

DCGI: Drug Controller General of India; Apex regulatory authority in India for granting approvals

Addressable pool of ~2 million patients in select markets for ZAYNICH® (WCK 5222)



Excluding: Rest of World, Japan & Russia

a) **China** : Adapted and derived using China incidence/epidemiology papers & CHINET China Bacterial Drug Resistance Surveillance Results (January-December 2022)
b) **India**: Adapted and derived using India incidence studies and ICMR Anti Microbial Resistance Research & Surveillance Network 2022
c) **US & Europe:** Adapted and derived using epidemiology data and carbapenem resistance to key pathogens

~1.1 Million cases in India addressable by ZAYNICH® (WCK 5222) for key indications



- Excludes Complicated Urinary Tract Infection patients due to available treatment options – select patients would be available as addressable patient pool for WCK 5222, which would be an upside
- Patient population derived on basis of ICMR AMR Report 2022 & other epidemiology data sources.

ZAYNICH® (WCK 5222) addressable market in India

Total cases affected by Key Pathogens (E.coli, Klebsiella P., Pseudomonas A., Acinetobacter B)	**~2.2 -3.1 Mn**
Carbapenem Resistance cases for key pathogens	**~1.4 -2.0 Mn**
Carbapenem resistance cases not treated by newer therapy options and addressable by WCK 5222	**~1.1 Mn**
Addressable market potential (INR Cr.)	**~INR 17K Crores**

WCK 5222 addressable market opportunity of ~US$ 7 billion in USA and Europe

Addresses major Gram-negative infections

cUTI, HABP/VABP, BSI, cIAI, indications

Pathogen coverage includes:

Carbapenem resistant Acinetobacter B (CRAB), Carbapenem resistant Enterobacterales (CRE), Carbapenem resistant Pseudomonas A (CRPA) & Carbapenem resistant Stenotrophomonas including MBL producers

~371K carbapenem resistant cases in US & Europe

~4.3 million hospitalized cases for key gram-negative pathogens

New class antibiotic WCK 5222 offers addressable market opportunity of ~US$ 7 billion in USA & Europe

MIQNAF® (Nafithromycin)

Next generation respiratory tract infection antibiotic

Wockhardt has ended a wait of > 30 years for a new antibiotic in Macrolide class with approval and launch of Miqnaf® (Nafithromycin)

MIQNAF® (Nafithromycin): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) & Upper Respiratory tract infections(RTI)



Increasing resistance and incomplete coverage for current treatment options:

- Macrolides (Azithromycin, Erythromycin) resistance in S. Pneumonia of ~65% in India
- Lack of atypical pathogen coverage by Amoxicillin/Clavulanic acid

Nafithromycin has broad spectrum (covers entire range of gram +ve, gram -ve & atypicals) enabling monotherapy; effective against Azithromycin resistant strains / multi-drug resistance bacteria with 100% coverage based on high lung concentrations

Best-in-class Lung concentration (Human lung exposure 8 times higher than Azithromycin) allowing for Ultra short duration therapy (3 day) with once-a-day dosing

Successfully completed phase III study with 96.77 % of cure rate in CABP and other respiratory infections, with safety profile commensurate with community usage

India Marketing approval granted and launched

QIDP status granted by USFDA indicating significant unmet need

Breakthrough Medicinal Product (BMP) designation granted in Saudi Arabia; NDA filed

MIQNAF® (Nafithromycin) outperforms current CABP 1st line treatment options in terms of efficacy, treatment options and safety

		MIQNAF® (Nafithromycin)	Macrolide Azithromycin	Macrolide Clarithromycin	Penicillin Amoxicillin + Clavulanic acid	Cephalosporin Cefixime / Cefpodoxime
	Resistance (%) in S. Pneumoniae + H. Influenza	0%	Up to 65%	Up to 65%	11%	Up to 42%
%Market size	Indian market size at generic prices (INR Cr.)*	NA	1,078	145	2,272	1,736
%Market size	Days of Therapy (Mn) #	NA	526	20	260	419
Anti-bacterial activity	Efficacy for macrolide-, penicillin- & quinolone-resistant *S. pneumoniae*	Yes	No	No	No	No
Anti-bacterial activity	Efficacy for atypical RTI[1] pathogens	Yes	Yes	Yes	No	No
Anti-bacterial activity	Coverage of *MDR H. influenzae*	Yes	No	No	No	No
Anti-bacterial activity	Prevalence of resistance	MOA driven low propensity	High	High	High	High
Treatment options	3-day therapy potential	Yes	Yes	No	No	No
Treatment options	Lung concentration for resistant strains	High	Low	Low	Low	Low
Treatment options	Pediatric use potential	Yes	Yes	Yes	Yes	Yes
Safety/ adverse events	Hepatic safety	Yes	Yes	Moderate	Yes	Yes
Safety/ adverse events	Drug-drug interaction potential	No	No	Moderate	No	No
Safety/ adverse events	*C. difficile* diarrhoea potential	No	No	No	Yes	Yes
IP	Patent protection	Assured	Expired	Expired	Expired	Expired

*Source: IQVIA

Derived from IQVIA

MIQNAF® (Nafithromycin): Addressable market in India

01

RTI is one of the leading Rx category in India with ~367 Mn Rx

- **62 Million Lower Respiratory Tract Infection Rx**
- **305 Million Upper Respiratory Tract Infection Rx**

02

Antibiotics market size for Respiratory Tract Infection (RTI) in India (at current generic prices) is ~INR 6,500 Cr.

03

Miqnaf® is targetting 96 Mn* Rx segment of relevant doctor specialities, with addressable market opportunity of ~INR 10,800 Cr.

* does not include potential upside of Rx by GP


Biotechnology

Competitive advantage in Diabetes Biosimilars: Integrated capabilities from lab to patient

Integrated capabilities

1

R&D Capabilities:

- Yeast, Bacterial & Mammalian expression
- Focused only on Diabetes segment - Insulin, Insulin Analogues
- Product development, process development, analytical development & analytical bio similarity

2

Drug Substance (DS) manufacturing

- DS facility with 4 blocks for different expression systems using E. coli, mammalian and yeast

3

Drug Product (DP) manufacturing

- Flexibility of drug product manufacturing at India facility (2 sites)

4

Devices

- Patented delivery devices (Disposable & Re-usable)

Commercialization model

India

- Through own field force for promotion to Diabetologists/ Endocrinologists

Emerging Market

- Through partners / distributors in >30 countries

Patented delivery devices (pen)

Vials

Cartridges

Diabetes Biosimilars for Emerging markets - Competitive scenario

Competitive scenario

1	Limited competition	6-7 players
2	Registered in emerging markets	>30 markets
3	Manufacturing infrastructure ready	Drug substance + Products
4	Integrated end to end capabilities	Development to marketing
5	Focus on Human Insulin & Glargine	> US$ 1.5 Billion market
6	Pipeline: Aspart R (filed in India) & Aspart Mix	~ US$ 700 Million market

Significant opportunity opening up in Human Insulin due to changing market dynamics

Change in market dynamics

Novo Nordisk intends to discontinue its Human disposable insulin pens and cartridges.

Initiative to increase production of GLP-1 analogues

₹ ~INR 450 Cr.

- **Novo Nordisk's** phase-out of Human Insulin cartridges and dispopen provides an **opportunity worth ~INR 450 Cr. In India**
- Only 3 key **players including Wockhardt to benefit from this opportunity**

Emerging Markets*

$ ~US$ 157 Mn

- **Novo Nordisk's** phase-out of Human Insulin cartridges and dispopen provides an **opportunity worth ~US $157 Mn in Emerging markets**

Wockhardt's strong position in Insulin will enable to capitalize this opportunity

*Emerging markets: excluding China & India

Comprehensive antidiabetic biosimilars pipeline across Human Insulin & Insulin analogs targeting India and Emerging Markets

Commercialized Products

1. **Recombinant Human Insulin**
2. **Glargine 100 IU**

Product Pipeline	Aspart R	Aspart 30/70	Lispro R
Process development	✓	✓	✓
Process Scale Up	✓	✓	✓*
Drug substance validation batches	✓	✓	✓*
Drug product validation batches	✓	✓	Planned
PK/PD study	✓	Planned	
Analytical similarity	✓		

✓ Completed
* To be further scaled up

Strategic growth levers

Robust Business performance driven by operational leverage

Novel Antibiotic Portfolio : Best-in-class portfolio across infection spectrum targeting high value global markets

Zaynich: A Breakthrough innovation

- Life-saving innovation for gram negative infections
- TAM of ~US$ 9 bn in US, Europe and India

Miqnaf: Oral Antibiotic for RTI

- New antibiotic in Macrolide class after > 30 years
- TAM of ~INR 10,800 Cr. in India

Diabetes Biosimilars

- Uniquely positioned diabetes portfolio (EM market size of US$ 3 bn) with end-to-end capabilities
- Doubling capacity in next 3 years to tap growing demand that would help business to grow at 20-25%

TAM: Total Addressable Market

Abbreviations

®: Registered
~: Approximate
A.baumannii: Acinetobacter baumannii
ABSSSI: Acute bacterial skin and skin structure infections
AmpC: Ampicillin-resistance gene group C
AMR: Anti Microbial Resistance
β-lactam: Beta Lactam
Bn: Billion
BSI: Blood Stream infection
CABP: Community-acquired bacterial pneumonia
CAZ/AVI: Ceftazidime-avibactam
CDSCO: Central Drugs Standard Control Organization
cIAI: Complicated Intra-abdominal Infections
CLSI: Clinical & Laboratory Standards Institute, USA
Cr.: Crore
CRAB: Carbapenem-Resistant Acinetobacter baumannii
cUTI : Complicated urinary tract infections
EBITDA : Earnings before interest, taxes, depreciation, and amortization
E.coli: Escherichia coli
EU: European Opinion
Gram –ve: Gram negative
Gram +ve: Gram positive
HABP: Hospital Acquired Bacterial Pneumonia
ICMR: Indian Council of Medical Research
ICU: Intensive care unit
IND: Investigational New Drug
INR: Indian rupee
IU – International Unit
IV: Intravenous
K Pneumoniae :Klebsiella pneumoniae
KPC: Klebsiella pneumoniae carbapenemase
MBL: Metallo-beta-lactamase
MDR: Multidrug resistance
MDR/XDR: Multi Drug Resistant/ Extremely drug resistant
Mn – Million
MOA: Mechanism of Action
MOH – Ministry of Health
MRSA: Methicillin-resistant Staphylococcus aureus
NCE: New chemical entity
NDA: New Drug Application
NIH: National Institute of Health
PhD: Doctor of Philosophy
PK: Pharmacokinetics
PK/PD – Pharmacokinetics/Pharmacodynamics
QIDP: Qualified Infectious Disease Product
R&D: Research and Development
RTI: Respiratory Tract Infection
S. maltophilia : Stenotrophomonas maltophilia
TID: Thrice a day
UK: United Kingdom
US: United States
US-FDA: United Stated Food and Drug Administration
VABP: Ventilator Acquired Bacterial Pneumonia
WHO: World Health Organization
Y-o-Y: Year-over-year

Saving Lives 55 years

WOCKHARDT | LIFE WINS

Thank you